# US 2017/0283801 A1 · Therapeutic compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283801 A1
- Document ID: US20170283801A1
- Status: Published application
- Kind: A1
- Application number: 15/623,139
- Filed: 2017-06-14
- Published: 2017-10-05
- Earliest claimed: 2003-03-07
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Muthiah MANOHARAN; Kallanthottathil G. RAJEEV; David BUMCROT
- Web page: https://patentgrep.com/patent/US20170283801A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07H 21/02: with ribosyl as saccharide radical
- C07K 14/775: Apolipopeptides
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/533: having a mismatch or nick in at least one of the strands
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N 2320/53: reducing unwanted side-effects
- C12N 2330/30: chemically synthesised
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This application relates to therapeutic siRNA agents and methods of making and using the agents.

## Claims

### Claim 1

An iRNA agent, comprising: a sense strand sequence having 4-12 asymmetrical 2′-O-alkyl modifications, at least 4 of which occur within the 6 terminal nucleotides of the 5′ end; and an antisense sequence having at least 4 asymmetrical phosphorothioate modifications.

### Claim 2 (depends on 1)

The iRNA agent of claim 1, wherein the sense and antisense sequences of the iRNA agent are on different RNA strands.

### Claim 3 (depends on 1)

The iRNA agent of claim 1, wherein the sense and antisense sequences of the iRNA agent are on the same RNA strand.

### Claim 4 (depends on 1)

The iRNA agent of claim 1, wherein the sense and antisense sequences of the iRNA agent are fully complementary to each other.

### Claim 5 (depends on 1)

The iRNA agent of claim 1, further comprising a cholesterol moiety, wherein the cholesterol moiety is coupled to the sense sequence of the iRNA agent.

### Claim 6 (depends on 1)

The iRNA agent of claim 1, wherein the iRNA agent is at least 21 nucleotides in length, and the duplex region of the iRNA agent is about 19 nucleotides in length.

### Claim 7 (depends on 1)

The iRNA agent of claim 1, the iRNA agent having a duplex region of about 19 nucleotides in length and one or two 3′ overhangs of about 2 nucleotides in length.

### Claim 8 (depends on 1)

The iRNA agent of claim 1, wherein the antisense sequence contains 4-20 asymmetrical phosphorothioate modifications.

### Claim 9 (depends on 1)

The iRNA agent of claim 1, wherein each of the 2′-O-alkyl modifications are 2′-O-methyl modifications.

### Claim 10 (depends on 1)

The iRNA agent of claim 1, wherein the sense strand further comprises at least one asymmetric modification selected from the group consisting of 2′-5′-linkages, L sugars, modified sugars, nucleobase modifications, cation groups, Zwitterionic groups, and conjugate groups.

### Claim 11 (depends on 10)

The iRNA agent of claim 10, wherein the modification is 2′-5′ linkages, and the 2′-5′ linkage is phosphorothioate.

### Claim 12 (depends on 10)

The iRNA agent of claim 10, wherein the modification is L sugars, and the L sugar is L ribose or L-arabinose sugar.

### Claim 13 (depends on 10)

The iRNA agent of claim 10, wherein the modification is modified sugars, and the modified sugar is a locked nucleic acid, hexose nucleic acid or cyclohexane nucleic acid.

### Claim 14 (depends on 10)

The iRNA agent of claim 10, wherein the conjugate group is naproxen, biotin, ibuprofen, folic acid, peptides or carbohydrates.

### Claim 15 (depends on 1)

The iRNA agent of claim 1, wherein the antisense strand further comprises at least one asymmetric modification selected from the group consisting of 2′-5′-linkages, L sugars, modified sugars, nucleobase modifications, cation groups, Zwitterionic groups, and conjugate groups.

### Claim 16 (depends on 15)

The iRNA agent of claim 15, wherein the modification is 2′-5′ linkages, and the 2′-5′ linkage is phosphorothioate.

### Claim 17 (depends on 15)

The iRNA agent of claim 15, wherein the modification is L sugars, and the L sugar is L ribose or L-arabinose sugar.

### Claim 18 (depends on 15)

The iRNA agent of claim 15, wherein the modification is modified sugars, and the modified sugar is a locked nucleic acid, hexose nucleic acid or cyclohexane nucleic acid.

### Claim 19 (depends on 1)

The iRNA agent of claim 1, wherein the sense strand has 4 asymmetrical 2′-O-alkyl modifications within the 6 terminal nucleotides of the 5′ end, and at least one 2′-O-alkyl modification in another portion of the sense strand.

### Claim 20 (depends on 15)

The iRNA agent of claim 15, wherein antisense strand does not contain any 2′-O-alkyl modifications, and the sense strand does not contain any phosphorothioate modifications.
